5300 MEMORIAL DRIVE, HOUSTON, TX
Investor Presentation
Reports First Quarter 2026 Financial Results and Provides Clinical Update on Pivotal MIRACLE Trial
Announces Imminent MIRACLE Trial Unblinding as Blinded Data Continue to Significantly Outperform Historical Benchmarks
Independent Cleveland Clinic Review Finds No Clinically Significant Cardiotoxicity with Annamycin in R/R AML Patients Dosed Beyond Conventional Anthracycline Limits
Secures Strategic Additional Patent, Strengthening Global Positioning of Annamycin
.2
Shareholder votes
Q1
Amended Annual Report
FY 2025
Q3
Q2
Prospectus filed pursuant to Rule 424(b)(3)
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Prospectus filed pursuant to Rule 424(b)(5)
Definitive Proxy Statement
PRE 14A
PRER14A
Additional Proxy Materials
Statement of Changes in Beneficial Ownership
Correspondence
Submission Upload